Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of daily alternating
thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated
Waldenstrom macroglobulunemia (WM). Thalidomide and lenalidomide are drugs that modulate the
immune system and have been shown to bring about responses in subjects with WM. However,
their use has been limited due to side effects. The investigators hypothesize that
alternating doses of thalidomide and lenalidomide may alleviate the side effects while
preserving the effectiveness of the therapies.